Can Adma Biologics (ADMA) Climb 25.5% to Reach the Level Wall Street Analysts Expect?

Core Viewpoint - Adma Biologics (ADMA) has seen a 5.8% increase in share price over the past four weeks, closing at $19.92, with analysts suggesting a potential upside of 25.5$25 [1] Price Targets - The average price target for ADMA ranges from a low of $24 to a high of$26, with a standard deviation of $0.82, indicating a relatively tight clustering of estimates [2] - The lowest estimate suggests a 20.5% increase from the current price, while the highest estimate indicates a 30.5% upside [2] Analyst Sentiment - Analysts show strong agreement regarding ADMA's potential for better earnings, as indicated by positive revisions in earnings estimates, which historically correlate with stock price movements [4][9] - The Zacks Consensus Estimate for the current year has risen by 5.4% over the past month, with three estimates increasing and no negative revisions [10] Zacks Rank - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [11] Conclusion on Price Targets - While consensus price targets may not be entirely reliable for predicting stock price movements, the direction indicated by these targets can serve as a useful guide for further research [12]